QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (54) Citing Articles via Google Scholar Google Scholar Articles by Skelton, K. H. Articles by Owens, M. J. Search for Related Content PubMed PubMed Citation Articles by Skelton, K. H. Articles by Owens, M. J.

 Previous Article  |  Next Article 

The Journal of Neuroscience, February 1, 2000, 20(3):1240-1248

Chronic Administration of the Triazolobenzodiazepine Alprazolam Produces Opposite Effects on Corticotropin-Releasing Factor and Urocortin Neuronal Systems

Kelly H. Skelton, Charles B. Nemeroff, David L. Knight, and Michael J. Owens

Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322

In view of the substantial preclinical evidence that supports a seminal role of central corticotropin-releasing factor (CRF) neuronal systems in the physiology and pathophysiology of stress and anxiety, it is reasonable to suggest that the anxiolytic properties of benzodiazepines are mediated, at least in part, via regulation of CRFergic function. To begin to test this complex hypothesis, we examined the effects of acute and chronic administration of the triazolobenzodiazepine agonist alprazolam on CRF peptide concentrations, receptor-binding density, and mRNA expression in the CNS. Additionally, we measured mRNA expression for urocortin, a recently discovered neuropeptide that is generally considered to be a second endogenous ligand for CRF receptors. Both acute and chronic alprazolam administration was found to decrease CRF concentrations within the locus coeruleus. Furthermore, chronic alprazolam decreased basal activity of the hypothalamic-pituitary-adrenal axis, CRF mRNA expression in the central nucleus of the amygdala, and CRF₁ mRNA expression and receptor binding in the basolateral amygdala. In marked contrast, urocortin mRNA expression in the Edinger-Westphal nucleus and CRF_2A receptor binding in the lateral septum and ventromedial hypothalamus were increased. Similar findings of an inverse relationship between the CRF₁ and CRF_2A receptor systems have been reported in an anxiety model based on adverse early-life experience, suggesting the intriguing possibility that CRF neuronal systems may be comprised of two separate, but interrelated, subdivisions that can be coordinately and inversely regulated by stress, anxiety, or anxiolytic drugs.

Key words: amygdala; anxiety; benzodiazepines; corticotropin-releasing factor; locus coeruleus; stress; urocortin

---

Copyright © 2000 Society for Neuroscience  0270-6474/00/2031240-09$05.00/0

This article has been cited by other articles:

				C Wallon, P-C Yang, A V Keita, A-C Ericson, D M McKay, P M Sherman, M H Perdue, and J D Soderholm Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro Gut, January 1, 2008; 57(1): 50 - 58. [Abstract] [Full Text] [PDF]

				K. H. Skelton, C. B. Nemeroff, and M. J. Owens Spontaneous Withdrawal from the Triazolobenzodiazepine Alprazolam Increases Cortical Corticotropin-Releasing Factor mRNA Expression J. Neurosci., October 20, 2004; 24(42): 9303 - 9312. [Abstract] [Full Text] [PDF]

				Z. Merali, L. Du, P. Hrdina, M. Palkovits, G. Faludi, M. O. Poulter, and H. Anisman Dysregulation in the Suicide Brain: mRNA Expression of Corticotropin-Releasing Hormone Receptors and GABAA Receptor Subunits in Frontal Cortical Brain Region J. Neurosci., February 11, 2004; 24(6): 1478 - 1485. [Abstract] [Full Text] [PDF]

				M. L. Gilmor, K. H. Skelton, C. B. Nemeroff, and M. J. Owens The Effects of Chronic Treatment with the Mood Stabilizers Valproic Acid and Lithium on Corticotropin-Releasing Factor Neuronal Systems J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 434 - 439. [Abstract] [Full Text] [PDF]

				R. K. Bachtell, N. O. Tsivkovskaia, and A. E. Ryabinin Alcohol-Induced c-Fos Expression in the Edinger-Westphal Nucleus: Pharmacological and Signal Transduction Mechanisms J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 516 - 524. [Abstract] [Full Text] [PDF]

				V. P. Bakshi, S. Smith-Roe, S. M. Newman, D. E. Grigoriadis, and N. H. Kalin Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala J. Neurosci., April 1, 2002; 22(7): 2926 - 2935. [Abstract] [Full Text] [PDF]

				J. Preil, M. B. Muller, A. Gesing, J. M. H. M. Reul, I. Sillaber, M. M. van Gaalen, J. Landgrebe, F. Holsboer, M. Stenzel-Poore, and W. Wurst Regulation of the Hypothalamic-Pituitary-Adrenocortical System in Mice Deficient for CRH Receptors 1 and 2 Endocrinology, November 1, 2001; 142(11): 4946 - 4955. [Abstract] [Full Text] [PDF]

				Z. Sarnyai, Y. Shaham, and S. C. Heinrichs The Role of Corticotropin-Releasing Factor in Drug Addiction Pharmacol. Rev., June 1, 2001; 53(2): 209 - 244. [Abstract] [Full Text] [PDF]

				L. Arborelius, K. H. Skelton, K. V. Thrivikraman, P. M. Plotsky, D. W. Schulz, and M. J. Owens Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 588 - 597. [Abstract] [Full Text]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help